Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
|Articles|March 23, 2022
Daily Medication Pearl: Octreotide (Sandostatin)
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Octreotide (Sandostatin)
Indications: Sandostatin is a somatostatin analogue indicated to treat severe diarrhea and flushing associated with certain types of metastatic carcinoid tumors. The drug is also used to treat acromegaly.
Insight:
- Dosing: 50 mcg 3 times daily, Sandostatin injection subcutaneously for 2 weeks followed by 20 mg intragluteally every 4 weeks for 3 months.
- Dosage forms: For injectable suspension, strengths 10 mg per 6 mL, 20 mg per 6 mL, or 30 mg per 6 mL vials.
- Adverse events: The most common adverse reactions, occurring in ≥ 20% of patients are diarrhea, cholelithiasis, abdominal pain, flatulence, back pain, fatigue, headache, abdominal pain, nausea, and dizziness.
- Mechanism of action: Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.
- Manufacturer: Novartis
Sources:
Advertisement
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
2
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
Understanding Kratom: Pharmacology, Safety, and Regulation
5